Filter Results:
(777)
Show Results For
- All HBS Web
(937)
- People (2)
- News (70)
- Research (777)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(937)
- People (2)
- News (70)
- Research (777)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Sort by
- March 1993 (Revised May 1998)
- Teaching Note
ImmuLogic Pharmaceutical Corporation (Series) TN
By: Josh Lerner
Teaching Note for (9-293-066--071) and (9-293-087). View Details
Keywords: Pharmaceutical Industry
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (D): Hatch-Waxman Change
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (D): Hatch-Waxman Change." Harvard Business School Supplement 806-067, January 2006. (Revised May 2007.)
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (B): Merger Decision
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (B): Merger Decision." Harvard Business School Supplement 806-065, January 2006. (Revised May 2007.)
- 1999
- Chapter
The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions Among Scientific, Institutional, and Organizational Change
By: Rebecca Henderson, Gary P. Pisano and Luigi Orsenigo
Keywords: Science-Based Business; Organizational Change and Adaptation; Transformation; Pharmaceutical Industry
Henderson, Rebecca, Gary P. Pisano, and Luigi Orsenigo. "The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions Among Scientific, Institutional, and Organizational Change." In Sources of Industrial Leadership: Studies of Seven Industries, edited by David Mowery and Richard Nelson. Cambridge University Press, 1999.
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details
Keywords: Mergers and Acquisitions; Growth and Development Strategy; Product Development; Research and Development; Corporate Strategy; Pharmaceutical Industry; United States
Collis, David J., and Troy Smith. "Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc." Harvard Business School Case 707-509, November 2006. (Revised November 2007.)
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross." Harvard Business School Supplement 293-070, October 1992. (Revised April 1993.)
- June 1990
- Teaching Note
International Pharmaceuticals Inc. (Abridged), Teaching Note
By: James E. Austin and Tomas Otto Kohn
Keywords: Pharmaceutical Industry
- 1995
- Chapter
Pharmaceutical Companies and Health Care Reform
By: Arthur A. Daemmrich
- April 1989 (Revised January 1994)
- Case
Novo Industri
By: Michael E. Porter and Michael J. Enright
Describes the structure of the insulin industry, a treatment for diabetes and Novo's strategy and competitive position in early 1982. The industry is undergoing significant change and Novo must decide how to defend and build its international position. Designed as an... View Details
Keywords: Change; Global Strategy; Industry Structures; Alliances; Competitive Strategy; Health Disorders; Pharmaceutical Industry
Porter, Michael E., and Michael J. Enright. "Novo Industri." Harvard Business School Case 389-148, April 1989. (Revised January 1994.)
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter." Harvard Business School Supplement 293-067, October 1992. (Revised March 1993.)
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (F): Appeals Court Ruling
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (F): Appeals Court Ruling." Harvard Business School Supplement 806-082, January 2006. (Revised May 2007.)
- March 2015
- Case
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
Over the course of a tumultuous weekend in April 2010, André Wyss was put in charge of Novartis Pharmaceuticals Corporation (NPC), the U.S. sales and marketing subsidiary of Novartis Pharma AG. He was brought in at a critical point in the organization's evolution with... View Details
Keywords: LEAD; Talent Management; Leadership And Change Management; Change Management; Organizational Change and Adaptation; Restructuring; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)." Harvard Business School Case 415-013, March 2015.
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (E): Judge Stein Rules
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (E): Judge Stein Rules." Harvard Business School Supplement 806-081, January 2006. (Revised May 2007.)
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk." Harvard Business School Supplement 293-069, October 1992. (Revised March 1993.)
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (C): April 1991
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (C): April 1991." Harvard Business School Supplement 293-071, October 1992. (Revised March 1993.)
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B2): Henry McCance
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B2): Henry McCance." Harvard Business School Supplement 293-068, October 1992. (Revised April 1993.)
- April 2015
- Supplement
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
This (B) case describes the actions André Wyss, president of Novartis Pharmaceuticals Corporation, took in early 2012 to transform the company's General Medicines group and build its specialty medications, marketing the selling capabilities in the face of falling... View Details
Keywords: LEAD; Leadership And Change Management; Talent Management; Organizational Change and Adaptation; Leadership; Change Management; Talent and Talent Management; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)." Harvard Business School Supplement 415-049, April 2015.
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (C): An "At Risk" Launch?
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. Endo Pharmaceuticals (C): An "At Risk" Launch? Harvard Business School Supplement 806-066, January 2006. (Revised May 2007.)
- June 2005
- Article
A Rising Drug Industry: Pharmaceuticals since 1870
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "A Rising Drug Industry: Pharmaceuticals since 1870." Chemical and Engineering News (June 2005), 28–42.
- June 1991
- Case
Eli Lilly and Co.: European Pharmaceutical Operations
Yoshino, Michael Y. "Eli Lilly and Co.: European Pharmaceutical Operations." Harvard Business School Case 391-234, June 1991.